Literature DB >> 7510686

Identification of a combinatorial epitope expressed by the integrin alpha 4 beta 1 heterodimer involved in the regulation of cell adhesion.

J L Bednarczyk1, M C Szabo, J N Wygant, A I Lazarovits, B W McIntyre.   

Abstract

The alpha 4 integrin subunit can associate with either the beta 1- or beta 7-integrin subunit to form two unique adhesion receptors alpha 4 beta 1 and alpha 4 beta 7. We developed a monoclonal antibody (mAb 19H8) that immunoprecipitated alpha 4 beta 1, induced homotypic leukocyte aggregation, and blocked the binding of cells to a synthetic peptide corresponding to the CS-1 peptide region of fibronectin. Aggregation cross-blocking analysis suggested that mAb 19H8 belonged to the group of mAbs that react with the B2 epitope of the alpha 4 subunit (alpha 4.B2 epitope); however, unlike the alpha 4.B2-specific mAb L25, mAb 19H8 did not immunoprecipitate alpha 4 beta 7. In addition, mAb 19H8 did not bind to beta 1-positive cells unless transfected with alpha 4 cDNA. These results indicated that mAb 19H8 was not specific for an individual alpha 4, beta 1, or beta 7 subunit but reacted with an epitope formed from the association of alpha 4 with beta 1. Separating the alpha 4 from the beta 1 subunit, by removing divalent cations or by treatment with high pH, disrupted mAb 19H8 binding. In contrast, the alpha 4-specific mAb L25 and the beta 1-specific mAb 18D3 could react with their respective subunits without subunit association. Therefore, mAb 19H8 defined a novel regulatory epitope expressed by the integrin alpha 4 beta 1.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7510686

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

Review 1.  The pathophysiologic role of alpha 4 integrins in vivo.

Authors:  R R Lobb; M E Hemler
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

2.  Integrin-mediated entry into S phase of human gastric adenocarcinoma cells.

Authors:  T Udagawa; V L Hopwood; S Pathak; B W McIntyre
Journal:  Clin Exp Metastasis       Date:  1995-11       Impact factor: 5.150

3.  B-Raf regulation of integrin α4β1-mediated resistance to shear stress through changes in cell spreading and cytoskeletal association in T cells.

Authors:  Wells S Brown; Jahan S Khalili; Tania G Rodriguez-Cruz; Greg Lizee; Bradley W McIntyre
Journal:  J Biol Chem       Date:  2014-06-16       Impact factor: 5.157

4.  Monoclonal antibodies to CD44 and their influence on hyaluronan recognition.

Authors:  Z Zheng; S Katoh; Q He; K Oritani; K Miyake; J Lesley; R Hyman; A Hamik; R M Parkhouse; A G Farr; P W Kincade
Journal:  J Cell Biol       Date:  1995-07       Impact factor: 10.539

5.  Control of T lymphocyte morphology by the GTPase Rho.

Authors:  Darren G Woodside; David K Wooten; T Kent Teague; Yuko J Miyamoto; Eva G Caudell; Taturo Udagawa; Bernard F Andruss; Bradley W McIntyre
Journal:  BMC Cell Biol       Date:  2003-02-24       Impact factor: 4.241

6.  Adenosine diphosphate (ADP)-ribosylation of the guanosine triphosphatase (GTPase) rho in resting peripheral blood human T lymphocytes results in pseudopodial extension and the inhibition of T cell activation.

Authors:  D G Woodside; D K Wooten; B W McIntyre
Journal:  J Exp Med       Date:  1998-10-05       Impact factor: 14.307

7.  CD25 and CD69 induction by α4β1 outside-in signalling requires TCR early signalling complex proteins.

Authors:  Ann-Marie Cimo; Zamal Ahmed; Bradley W McIntyre; Dorothy E Lewis; John E Ladbury
Journal:  Biochem J       Date:  2013-08-15       Impact factor: 3.857

8.  The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells.

Authors:  Stefania Fiorcari; Wells S Brown; Bradley W McIntyre; Zeev Estrov; Rossana Maffei; Susan O'Brien; Mariela Sivina; Julia Hoellenriegel; William G Wierda; Michael J Keating; Wei Ding; Neil E Kay; Brian J Lannutti; Roberto Marasca; Jan A Burger
Journal:  PLoS One       Date:  2013-12-23       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.